Research Analysts’ Recent Ratings Changes for Harvard Bioscience (HBIO)

Several brokerages have updated their recommendations and price targets on shares of Harvard Bioscience (NASDAQ: HBIO) in the last few weeks:

• 4/28/2025 – Harvard Bioscience is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 4/20/2025 – Harvard Bioscience is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 4/12/2025 – Harvard Bioscience is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 4/9/2025 – Harvard Bioscience had its “sector weight” rating reaffirmed by analysts at KeyCorp.
• 3/24/2025 – Harvard Bioscience had its price target lowered by analysts at Benchmark Co. from $5.50 to $4.50. They now have a “speculative buy” rating on the stock.

Harvard Bioscience Price Performance

Shares of HBIO opened at $0.38 on Tuesday. The company has a current ratio of 2.06, a quick ratio of 0.91 and a debt-to-equity ratio of 0.52. Harvard Bioscience, Inc. has a 1 year low of $0.36 and a 1 year high of $4.08. The stock has a market cap of $16.91 million, a P/E ratio of -1.16 and a beta of 1.47. The stock’s 50-day moving average price is $0.60 and its two-hundred day moving average price is $1.56.

Hedge Funds Weigh In On Harvard Bioscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Street Corp boosted its holdings in Harvard Bioscience by 1.1% during the third quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier’s stock worth $1,930,000 after buying an additional 7,763 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Harvard Bioscience by 63.0% during the third quarter. JPMorgan Chase & Co. now owns 29,501 shares of the medical instruments supplier’s stock worth $79,000 after buying an additional 11,397 shares during the last quarter. Bank of America Corp DE boosted its holdings in Harvard Bioscience by 44.4% during the fourth quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock worth $82,000 after buying an additional 11,948 shares during the last quarter. Jane Street Group LLC raised its position in shares of Harvard Bioscience by 55.5% during the fourth quarter. Jane Street Group LLC now owns 35,769 shares of the medical instruments supplier’s stock worth $75,000 after purchasing an additional 12,767 shares during the period. Finally, Focus Partners Wealth acquired a new stake in shares of Harvard Bioscience during the fourth quarter worth about $28,000. Institutional investors own 80.87% of the company’s stock.

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.